

Tuberculosis profile: South Africa

Population 2022: 60 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	280 000 (182 000-398 000)	468 (304-665)
HIV-positive TB incidence	152 000 (99 000-217 000)	255 (166-362)
MDR/RR-TB incidence**	11 000 (6 700-16 000)	19 (11-26)
HIV-negative TB mortality	23 000 (22 000-24 000)	39 (37-41)
HIV-positive TB mortality	31 000 (9 900-64 000)	52 (17-107)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	2.9% (2.8-3)
Previously treated cases	10% (10-11)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	77% (54-120)
TB patients facing catastrophic total costs, 2021	56% (49-63)
TB case fatality ratio (estimated mortality/estimated incidence), 2022	20% (9-34)

TB case notifications, 2022

Total new and relapse	214 295
- % tested with rapid diagnostics at time of diagnosis	74%
- % with known HIV status	88%
- % pulmonary	88%
- % bacteriologically confirmed ^	70%
- % children aged 0-14 years	7%
- % women (aged ≥15 years)	38%
- % men (aged ≥15 years)	55%
Total cases notified	224 621

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	102 254	54%
- on antiretroviral therapy	90 363	88%

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	90%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	6 781
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	6 940
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	809
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	711
MDR/RR-TB cases tested for resistance to any fluoroquinolone	684

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	79%	161 359
Previously treated cases, excluding relapse, registered in 2021	60%	8 327
HIV-positive TB cases registered in 2021	79%	87 187
MDR/RR-TB cases started on second-line treatment in 2020	62%	6 235
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	53%	807


TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	62%
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	6% (5.8-6.1)


Funding for TB

Funding for TB, 2022 (US\$ millions)	0
- % domestic funding	
- % international funding	
National TB budget, 2023 (US\$ millions)	144
- Funding source, domestic	83%
- Funding source, international	17%
- Unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022 (Number)



Cases attributable to five risk factors, 2022 (Number)



Funding for TB (US\$ millions)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed

Generated 2024-04-05 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)